TORONTO, March 02, 2017 -- The Shawcor Ltd. (TSX:SCL) Board of Directors today declared a dividend of fifteen cents (15.00 cents) per share on the outstanding common shares of the Corporation payable on the 31st day of March 2017, to shareholders of record at the close of business on the 17th day of March 2017.
For Canadian resident shareholders, these dividends are designated as "eligible dividends" for purposes of the enhanced dividend tax credit rules contained in the Income Tax Act (Canada) and any corresponding provincial and territorial tax legislation.
For further information, please contact: Gary S. Love Senior Vice President, Finance and CFO Telephone: 416.744.5818 e-mail: [email protected] website: www.shawcor.com


Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 



